Atmaram Vidyapeeth (Deemed to be University)Poona College of Pawar

Dr. Atmaram Vidyapeeth (Deemed to be University)Poona College of Pawar

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
RDRushikesh Shankarsa Dhudum
Rushikesh Shankarsa Dhudum
AGAnkit Ganeshpurkar
Ankit Ganeshpurkar
APAtmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
Atmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
The drug discovery and development process is very lengthy, highly expensive, and extremely complex in nature. Considering the time and cost constraints associated with conventional drug discovery, new methods must be found to enhance the declining efficiency of traditional approaches. Artificial intelligence (AI) has emerged as a powerful tool that harnesses anthropomorphic knowledge and provides expedited solutions to complex challenges. Advancements in AI and machine learning (ML) techniques have revolutionized their applications to drug discovery and development. This review illuminates the profound influence of AI on diverse aspects of drug discovery, encompassing drug-target identification, molecular properties, compound analysis, drug development, quality assurance, and drug toxicity assessment. ML algorithms play an important role in testing systems and can predict important aspects such as the pharmacokinetics and toxicity of drug candidates. This review not only strengthens the theoretical foundation and development of this technology, but also explores the myriad challenges and promising prospects of AI in drug discovery and development. The combination of AI and drug discovery offers a promising strategy to overcome the challenges and complexities of the pharmaceutical industry.

4 March 2025 in Drugs and Drug Candidates
Verified
Journal Article
Open access
PDF file
PKPriyanka Kandhare
Priyanka Kandhare
MKMrunal Kurlekar
Mrunal Kurlekar
TDTanvi Tanvi Deshpande
Tanvi Tanvi Deshpande
APAtmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
Atmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
Background/Objectives: The integration of Artificial Intelligence (AI) and Machine Learning (ML) in pharmaceutical research and development is transforming the industry by improving efficiency and effectiveness across drug discovery, development, and healthcare delivery. This review explores the diverse applications of AI and ML, emphasizing their role in predictive modeling, drug repurposing, lead optimization, and clinical trials. Additionally, the review highlights AI’s contributions to regulatory compliance, pharmacovigilance, and personalized medicine while addressing ethical and regulatory considerations. Methods: A comprehensive literature review was conducted to assess the impact of AI and ML in various pharmaceutical domains. Research articles, case studies, and industry reports were analyzed to examine AI-driven advancements in predictive modeling, computational chemistry, clinical trials, drug safety, and supply chain management. Results: AI and ML have demonstrated significant advancements in pharmaceutical research, including improved target identification, accelerated drug discovery through generative models, and enhanced structure-based drug design via molecular docking and QSAR modeling. In clinical trials, AI streamlines patient recruitment, predicts trial outcomes, and enables real-time monitoring. AI-driven predictive maintenance, process optimization, and inventory management have enhanced efficiency in pharmaceutical manufacturing and supply chains. Furthermore, AI has revolutionized personalized medicine by enabling precise treatment strategies through genomic data analysis, biomarker discovery, and AI-driven diagnostics. Conclusions: AI and ML are reshaping pharmaceutical research, offering innovative solutions across drug discovery, regulatory compliance, and patient care. The integration of AI enhances treatment outcomes and operational efficiencies while raising ethical and regulatory challenges that require transparent, accountable applications. Future advancements in AI will rely on collaborative efforts to ensure its responsible implementation, ultimately driving the continued transformation of the pharmaceutical sector.

26 November 2022 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
RPRanjitsinh Pawar
Ranjitsinh Pawar
APAtmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
Atmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
Background: The three-dimensional (3D) printing is paradigm shift in the healthcare sector. 3D printing is platform technologies in which complex products are developed with less number of additives. The easy development process gives edge over the conventional methods. Every individual needs specific dose treatment. ‘One size fits all’ is the current traditional approach that can shift to more individual specific in 3D printing. The present review aims to cover different perspectives regarding selection of drug, polymer and technological aspects for 3D printing. With respect to clinical practice, regulatory issue and industrial potential are also discussed in this paper. Main body: The individualization of medicines with patient centric dosage form will become reality in upcoming future. It provides individual’s need of dose by considering genetic profile, physiology and diseased condition. The tailormade dosages with unique drug loading and release profile of different geometrical shapes and sizes can easily deliver therapeutic dose. The technology can fulfill growing demand of efficiency in the dose accuracy for the patient oriented sectors like pediatric, geriatric and also easy to comply with cGMP requirements of regulated market. The clinical practice can focus on prescribing each individual’s necessity of dose. Conclusion: In the year 2015, FDA approved first 3D printed drug product, which is initiator in the new phase of manufacturing of pharmaceuticals. The tailormade formulations can be made in future for personalized medications. Regulatory approval from agencies can bring the 3DP product into the market. In the future, formulators can bring different sector-specific products for personalized need through 3DP pharmaceutical product. Graphical

25 January 2018 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Open access
BCBothiraja Chellampillai
Bothiraja Chellampillai
NRNeeti Rajput
Neeti Rajput
IPIshwor Poudel
Ishwor Poudel
SRS. Rajalakshmi
S. Rajalakshmi
BPBijoy Panda
Bijoy Panda
APAtmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
Atmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
A new family of biofunctionalized chitosan decorated nanocochleates-mediated drug delivery system was developed that involves uniquely combining nanocochleates with anticancer drug for controlled drug release, targeted delivery, improved bioavailability with reduced toxicity. This system was developed by loading of doxorubicin (DOX) to nanocochleates (DOX-NC) through conversion of negatively charged dimyristoylphosphatidylcholine (DMPC) phospholipid and cholesterol-bearing vesicles on addition of calcium ions, followed by encapsulation DOX-NC with folic acid conjugated chitosan (FA-CHI-DOX-NC). The release of DOX indicated strong pH dependence and implies hydrogen-bonding interaction between nanocochleates and DOX. Formulated FA-CHI-DOX-NC demonstrated higher in-vitro anticancer activity in folate overexpressed human breast cancer MCF-7 cells. The targeting effect for the FA-CHI-DOX-NC was also demonstrated. The concentration of the drug needed for growth inhibition of 50% of cells in a designed time period (GI50) was 9.1 µg/ml for DOX while it was decreased by 31.68% for the DOX-NC (6.2 µg/ml). Furthermore, the GI50 value of FA-CHI-DOX-NC was 4.4 µg/ml, i.e. a 51.64% decrease was observed as compared to DOX solution. Moreover, bioavailability of DOX from FA-CHI-DOX-NC increased by 4-fold with long circulation time, slower plasma elimination and no sign of tissue toxicity as compared to DOX solution. The proposed strategy is advantageous in terms of targeted drug delivery and has high potential to address the current challenges in drug delivery. Thus, the prepared new carrier offers a novel formulation that combines the unique properties of a biodegradable material, chitosan and nanocochleates for biomedical applications.

2 June 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SKSwati Korake
Swati Korake
CBC. Bothiraja
C. Bothiraja
APAtmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
Atmaram Vidyapeeth (Deemed to be University)Poona College of Pawar

1 February 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SKS. Korake
S. Korake
ASA. Shaikh
A. Shaikh
RSR. Salve
R. Salve
KGK.R. Gajbhiye
K.R. Gajbhiye
VGV. Gajbhiye
V. Gajbhiye
APAtmaram Vidyapeeth (Deemed to be University)Poona College of Pawar
Atmaram Vidyapeeth (Deemed to be University)Poona College of Pawar